<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109832</url>
  </required_header>
  <id_info>
    <org_study_id>IMP4297-109</org_study_id>
    <nct_id>NCT05109832</nct_id>
  </id_info>
  <brief_title>A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects</brief_title>
  <official_title>A Clinical Trial of the Absorption, Metabolism, and Excretion of [14C]IMP4297 in Chinese Adult Male Healthy Volunteers - A Human Material Balance and Biotransformation Study of [14C]IMP4297</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impact Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impact Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of&#xD;
      [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design A Phase I, single-center, open-label, single arm study is designed to evaluate&#xD;
      Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral&#xD;
      Dose to China Healthy Male Subjects.&#xD;
&#xD;
      6-8 subjects are planned to be enrolled (at least 6 subjects complete the study)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum concentration)</measure>
    <time_frame>3 months</time_frame>
    <description>peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>3 months</time_frame>
    <description>Time to peak</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area under the curve from time 0 to infinity)</measure>
    <time_frame>3 months</time_frame>
    <description>area under the curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)</measure>
    <time_frame>3 months</time_frame>
    <description>AUC0-last area under the curve from time zero to the time with the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ (Elimination half-life)</measure>
    <time_frame>3 months</time_frame>
    <description>elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (Apparent clearance)</measure>
    <time_frame>3 months</time_frame>
    <description>apparent clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution )</measure>
    <time_frame>3 months</time_frame>
    <description>apparent volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine and fecal samples for quantification analysis</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of recovery percent in urine and feces by liquid chromatography-radiochemical-detection。 Get Percent (%) of each radiolabeled drug-related material will be determined in urine and feces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>After oral administration of [14C] IMP4297 in healthy volunteers, radioactive metabolite spectrogram are obtained to identify the main metabolites and clarify the main biotransformation pathways.</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of different metabolites，Assessment of metabolites (metabolites identification and main metabolites) in plasma/urine/faeces by liquid chromatography-radiochemical-detection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>14C-IMP4297</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, one 100 mg dose of 14C IMP4297 Oral Suspension, 100 mg (100 μCi).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-IMP4297</intervention_name>
    <description>14C marked IMP4297</description>
    <arm_group_label>14C-IMP4297</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers must meet all of the following inclusion criteria to be included in the&#xD;
             study:&#xD;
&#xD;
               1. Volunteers must fully understand the objective, nature, methods and possible&#xD;
                  adverse reactions of the trial, volunteer to be volunteers, and sign an informed&#xD;
                  consent form before the start of any study procedures, and at the same time&#xD;
                  guarantee that the volunteers will personally participate in the study during any&#xD;
                  procedures.&#xD;
&#xD;
               2. Chinese healthy male volunteers aged between 18 and 55 (including cut-off values)&#xD;
                  at the time of screening.&#xD;
&#xD;
               3. Volunteers with a body mass index (BMI) of 18.0-28.0 kg/m2 (including cut-off&#xD;
                  values), and a body weight of ≥ 50.0 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers who meet any of the following criteria cannot be included in this study:&#xD;
&#xD;
               1. Diseases with abnormal clinical manifestations that need to be excluded,&#xD;
                  including but not limited to diseases of the nervous system, cardiovascular&#xD;
                  system, blood and lymphatic system, immune system, kidney, liver,&#xD;
                  gastrointestinal tract, respiratory system, metabolism and bones.&#xD;
&#xD;
               2. A history of allergic diseases (including drug allergies and food allergies,&#xD;
                  etc.).&#xD;
&#xD;
               3. A history of any gastrointestinal diseases that will affect drug absorption such&#xD;
                  as dysphagia, irritable bowel syndrome, and inflammatory bowel disease; active&#xD;
                  hemorrhoids or perianal diseases accompanied by regular/current blood in the&#xD;
                  stool; habitual constipation or diarrhea.&#xD;
&#xD;
               4. Those who have undergone surgery within 3 months before screening, or who plan to&#xD;
                  undergo surgery during the study period, and those who have undergone surgery&#xD;
                  that will affect drug absorption, metabolism, or excretion.&#xD;
&#xD;
               5. Those who cannot tolerate venipuncture, and those who have a history of needke&#xD;
                  sickness and blood phobia.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daisy Wang</last_name>
    <phone>86 13816512953</phone>
    <email>daisy.wang@impacttherapeutics.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

